← Back to Search

Monoclonal Antibodies

The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (WEE1 Trial)

Phase 1
Recruiting
Research Sponsored by Impact Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through 30 days after last dose, estimated to be 5 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug to see if it is effective and safe in treating advanced solid tumors.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through 30 days after last dose, estimated to be 5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 through 30 days after last dose, estimated to be 5 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part 1 Dose Escalation: Recommended Phase 2 Dose (RP2D) of IMP7068 monotherapy
Part 2 Dose Expansion: Overall Response Rate (ORR)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: IMP7068Experimental Treatment1 Intervention
Part 1: Dose Escalation The study will begin with open-label dose escalation in IMP7068 monotherapy treatment to determine the Maximum tolerated dose (MTD) Part 2: Dose Expansion The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. A total of 100 patients each with advanced solid tumor who has exhausted available treatment options will be evaluated.

Find a Location

Who is running the clinical trial?

CovanceIndustry Sponsor
120 Previous Clinical Trials
12,617 Total Patients Enrolled
Impact Therapeutics, Inc.Lead Sponsor
14 Previous Clinical Trials
1,200 Total Patients Enrolled
~72 spots leftby Dec 2025